排序
Depression Predisposes Parkinson Disease, Associated With Worse Disease Severity
Using data from more than 430,000 participants with 14.1 years of follow-up, findings from a recently published study showed that depression is common in patients with Parkinson di...
Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim
In a randomized, placebo-controlled trial, bezisterim (BioVie), an oral, small molecule, blood-brain permeable compound in development for Alzheimer disease (AD), demonstrated pote...
FDA Grants Breakthrough Therapy Designation for AOC 1001 in Myotonic Dystrophy Type 1
Sarah Boyce(Credit: Avidity)According to a recent announcement, the FDA has granted breakthrough therapy designation to AOC 1001 (Avidity Biosciences), an investigational treatment...
Importance of Nonmotor Features When Diagnosing Epilepsy in Adolescents
Jacqueline A. French, MDCredit: NYU LangoneAccording to a recently published study in Neurology, findings showed that nonmotor seizures go undetected two-thirds of the time in pedi...
CSF Anti-DAGLA Autoantibodies Identified as Potential Biomarker of Rapidly Progressive Cerebellitis
Kurt-Wolfram Sühs, MD(Credit: Hannover Medical School)In a small-scale study published in the Journal of Neurology, Neurosurgery & Psychiatry, investigators identified diacylglyce...
Basal Ganglia Activity Associated With REM Sleep Behavior Disorder in Parkinson Disease
Jian-Guo Zhang, MD, PhD(Credit: Capital Medical University)Newly published in the Journal of Neurology, Neurosurgery and Psychiatry, findings showed that basal ganglia activities a...
This Week on NeurologyLive® — May 13 2024
Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive®, there are a number of hot topics that we will be post...
Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680
Craig Hopkinson, MD(Credit: LinkedIn)According to a recent announcement, Alkermes has initiated its randomized, double-blind, dose-range-finding, placebo-controlled phase 2 Vibranc...